Published in Schizophr Bull on January 01, 2002
Childhood trauma and psychotic disorders: a systematic, critical review of the evidence. Schizophr Bull (2007) 1.45
Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat (2007) 1.03
Psychometrics properties of early trauma inventory self report - short form (ETISR-SR) for the Brazilian context. PLoS One (2013) 0.79
Predictors of community functioning in schizophrenia and substance use disorder patients. Community Ment Health J (2012) 0.75
Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol (2005) 8.49
Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81
The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology (2008) 4.35
When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry (2003) 3.68
Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry (2006) 3.33
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 3.24
Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry (2002) 3.05
Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry (2004) 2.83
Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun (2006) 2.78
Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun (2007) 2.75
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry (2013) 2.68
Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun (2005) 2.52
Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer (2003) 2.48
Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology (2011) 2.31
Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther (2011) 2.12
Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry (2003) 2.05
Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry (2008) 1.96
Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs (2005) 1.93
Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry (2003) 1.92
Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry (2003) 1.90
A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation (2004) 1.87
Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry (2005) 1.80
The role of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women: a multiple regression analysis. Depress Anxiety (2002) 1.72
Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry (2008) 1.70
Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology (2007) 1.63
Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol (2005) 1.63
Is depression an inflammatory disorder? Curr Psychiatry Rep (2011) 1.60
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry (2005) 1.58
Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry (2007) 1.51
Characterization of an interleukin-6- and adrenocorticotropin-dependent, immune-to-adrenal pathway during viral infection. Endocrinology (2004) 1.51
Adherence to the mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: a twin study. Circulation (2007) 1.51
Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry (2012) 1.48
Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun (2004) 1.43
Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol (2010) 1.38
Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol (2012) 1.35
IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun (2008) 1.30
Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci (2009) 1.30
Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord (2009) 1.28
Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry (2008) 1.27
Pituitary-adrenal responses to standard and low-dose dexamethasone suppression tests in adult survivors of child abuse. Biol Psychiatry (2004) 1.26
Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol Psychiatry (2010) 1.14
Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology (2007) 1.13
Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun (2012) 1.11
Breast cancer and depression. Oncology (Williston Park) (2004) 1.08
Alterations in diurnal salivary cortisol rhythm in a population-based sample of cases with chronic fatigue syndrome. Psychosom Med (2008) 1.06
Inhibition of Jun N-terminal kinase (JNK) enhances glucocorticoid receptor-mediated function in mouse hippocampal HT22 cells. Neuropsychopharmacology (2005) 1.01
Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study. Psychosom Med (2008) 1.01
Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology (2005) 1.00
Association between posttraumatic stress disorder and inflammation: a twin study. Brain Behav Immun (2013) 0.99
Genetic and environmental influences on systemic markers of inflammation in middle-aged male twins. Atherosclerosis (2008) 0.99
Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain Behav Immun (2013) 0.98
Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol (2011) 0.98
Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer (2013) 0.97
Treatment of cytokine-induced depression. Brain Behav Immun (2002) 0.94
Serotonin transporter gene, depressive symptoms, and interleukin-6. Circ Cardiovasc Genet (2009) 0.93
Chronic interferon-α decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology (2013) 0.93
Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain Behav Immun (2011) 0.92
Interferon-alpha inhibits glucocorticoid receptor-mediated gene transcription via STAT5 activation in mouse HT22 cells. Brain Behav Immun (2009) 0.92
Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse. Schizophr Res (2004) 0.91
Cognitive dysfunction relates to subjective report of mental fatigue in patients with chronic fatigue syndrome. Neuropsychopharmacology (2006) 0.89
Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav Immun (2013) 0.89
Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs. Expert Opin Ther Targets (2008) 0.89
Neuropsychological performance in persons with chronic fatigue syndrome: results from a population-based study. Psychosom Med (2008) 0.86
Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. Am J Drug Alcohol Abuse (2003) 0.86
Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull (2002) 0.86
Role of inflammation in depression: implications for phenomenology, pathophysiology and treatment. Mod Trends Pharmacopsychiatri (2013) 0.86
Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology (2012) 0.84
Neonatal viral infection decreases neuronal progenitors and impairs adult neurogenesis in the hippocampus. Neurobiol Dis (2002) 0.84
Do cytokines really sing the blues? Cerebrum (2013) 0.84
Inflammation in depression: is adiposity a cause? Dialogues Clin Neurosci (2011) 0.83
Cytokines, p38 MAP kinase and the pathophysiology of depression. Neuropsychopharmacology (2006) 0.83
Three independent techniques localize expression of transcript afp-11 and its bioactive peptide products to the paired AVK neurons in Ascaris suum: in situ hybridization, immunocytochemistry, and single cell mass spectrometry. ACS Chem Neurosci (2012) 0.82
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. J Psychiatr Res (2006) 0.81
Collagen scaffolds in bone sialoprotein-mediated bone regeneration. ScientificWorldJournal (2013) 0.80
Synthesis, fluorine-18 radiolabeling, and in vitro characterization of 1-iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivatives as potential PET radioligands for imaging peripheral benzodiazepine receptor. Bioorg Med Chem (2008) 0.80
Activation of cAMP-protein kinase A abrogates STAT5-mediated inhibition of glucocorticoid receptor signaling by interferon-alpha. Brain Behav Immun (2011) 0.80
Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. Neuropsychopharmacology (2002) 0.79
Ribavirin may be an important factor in IFN-induced neuropsychiatric effects. J Clin Psychiatry (2004) 0.78
On redefining the role of the immune system in psychiatric disease. Biol Psychiatry (2006) 0.78
Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors. Psychooncology (2014) 0.78
The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings. Neuropsychopharmacology (2013) 0.78
Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor. AJR Am J Roentgenol (2014) 0.77
[Neuro-immune interactions in psychopathology with the example of interferon-alpha-induced depression]. J Soc Biol (2003) 0.77
Association of IL-12p70 and IL-6:IL-10 ratio with autism-related behaviors in 22q11.2 deletion syndrome: a preliminary report. Brain Behav Immun (2013) 0.77
Interleukin-1 mediates long-term hippocampal dentate granule cell loss following postnatal viral infection. J Mol Neurosci (2009) 0.76
Letter to the Editor Re: "an inflammatory review of glucocorticoids in the CNS" by Sorrells et al. Brain, Behavior and Immunity 21, 259-272, 2007. Brain Behav Immun (2007) 0.76
Neurotherapeutic implications of brain-immune interactions. Neuropsychopharmacology (2014) 0.76
Pain Intensity and Pain Interference in Patients With Lung Cancer: A Pilot Study of Biopsychosocial Predictors. Am J Clin Oncol (2015) 0.76